Document
type: Class

Current Analytical Chemistry
type: Collection
type: Continuant
type: Document
type: Information Content Entity
type: Entity
publication venue for: New analytical method for simultaneous analysis of losartan and e-3174 by hplc in human plasma: Application in pharmaceutical science
type: Periodical
type: Generically Dependent Continuant
type: Thing
type: Journal

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

individual
rights: termsOfUse
date: 2026-08-24T21:49:54
publisher: vivo
type: Document
label: RDF description of New analytical method for simultaneous analysis of losartan and e-3174 by hplc in human plasma: Application in pharmaceutical science - http://orbis.uaslp.mx/vivo/individual/scopus6465

Article
type: Class

Information Content Entity
type: Class

New analytical method for simultaneous analysis of losartan and e-3174 by hplc in human plasma: Application in pharmaceutical science
related by: authorship_42035
has funding vehicle: M0018-2014-2
type: Continuant
type: Generically Dependent Continuant
most specific type: Article
origen: scopus
issue: 8
related by: authorship_42036
type: Article
related by: authorship_42037
crisid: 6466
doi: 10.2174/1573411015666191209111221
most specific type: Document
related by: authorship_42034
type: Information Content Entity
related by: authorship_42038
related by: authorship_42039
page start: 979
type: Entity
freetext keyword: E-3174; Heart failure; Losartan; Method validation; Pharmacokinetic; UV/VIS HPLC
abstract: Background: Losartan, one of the most frequently used drugs in Heart Failure (HF) treatment, could be modified for its bioavailability (BA) by generic formulations and other factors. Hence, the importance of therapeutic drug monitoring. Objective: Development and validation of a simplified analytical method using HPLC for simultaneous quantification of losartan and E-3174 in human plasma samples. The method was tested for determining the pharmacokinetics parameters of HF patients. Methods: Analytical conditions were optimized using a C18 column (4.6 X 50 mm, 3 µm. Thermo Scientific) at 25ºC. Conditions of mobile phase: a phosphate buffer (0.01M), adjusted to pH 2.5 with phosphoric acid (1M) and Acetonitrile (60:40 v/v). The flow rate was maintained at 1.2 mL/min, on a running time of 5 min and a sample injection volume of 50 µL. Absorbance for measurement of losartan and E-3174 was 200 nm. Pharmacokinetics profiles were determined with Phoenix WinNonlin 8.1 software in a non-compartmental model. Results: Analytical method developed and validated in this work is precise and accurate for simultaneous determination of losartan and E-3174 in human plasma samples in a range of 0.02-10 µg/mL. In HF subjects, lower Tmax and higher Cmax for losartan and E-3174 patent than generic formulation were observed, which can be translated into less biological effect and more time to present it by the generic drug. Conclusion: The pharmacokinetic profile is dependent on the type of formulation studied (generic/patent) hence the importance of conducting evaluations in our patients to ensure that the expected therapeutic effect is achieved with treatment administered. © 2020 Bentham Science Publishers.
type: Document
type: Thing
estado: published
date time value: article date 6466
volume: 16
has publication venue: Current Analytical Chemistry
e iscopus: 2-s2.0-85092228753
page end: 987

M0018-2014-2
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
funding vehicle for: New analytical method for simultaneous analysis of losartan and e-3174 by hplc in human plasma: Application in pharmaceutical science